About Solistaa
Solistaa is a company based in Puducherry (India). The company has 118 employees. Solistaa offers products and services including Gummies and Tablets.
- Headquarter Puducherry, India
- Employees 118
- SectorsHealthcare
- Email••••••••
- Social LinkedIn
- Legal Name Solistaa Pharmaceuticals Private Limited
- Date of Incorporation 27 Nov, 2017
- Jurisdiction Puducherry, India
- Annual Revenue₹57.79 Cr
FY 2025 · +8% YoY
- Net Profit₹37.4 Lakh
FY 2025 · 1% margin
- EBITDA₹7.49 Cr
FY 2025 · 13% margin
- Employee Count118
Associated legal entities of Solistaa
Solistaa operates through Solistaa Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Solistaa Pharmaceuticals Private Limited CIN U24304PY2017PTC008222 | Active | 27 Nov 2017 | Puducherry, Puducherry | ₹57.8 Cr | 118 | 3 | View details |
Products & Services of Solistaa
Solistaa offers a comprehensive portfolio of products and services, including Gummies and Tablets.
Gummies are produced as a dosage form for nutraceuticals to meet dietary supplement demands.
Tablets are manufactured for use in dietary supplements and related health applications.
Board of directors of Solistaa Pharmaceuticals Private Limited (Solistaa)
Solistaa Pharmaceuticals Private Limited is the primary company behind Solistaa. The board of Solistaa Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Paramasivan Sivarajakumar, appointed in 2017. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Paramasivan Sivarajakumar DIN 06520906 | Director | 27 Nov 2017 | 8 yrs 10 mo | Solistaa Pharmaceuticals Private Limited |
| Kandoth Kunnumpreth Vinupal DIN 03552323 | Director | 27 Nov 2017 | 8 yrs 10 mo | Solistaa Pharmaceuticals Private Limited |
| Sundararajalu DIN 07791111 | Director | 30 Jan 2018 | 8 yrs 8 mo | Solistaa Pharmaceuticals Private Limited |
Financials of Solistaa
Figures of Solistaa Pharmaceuticals Private Limited, the primary company behind Solistaa, for FY 2025. Revenue was ₹57.79 Cr (+8% year on year). Net profit was ₹37.4 Lakh (1% margin). EBITDA was ₹7.49 Cr (13% margin). Revenue has grown at a compounded annual rate of +8% over three years and +26% over five years.
- ₹57.79 CrRevenue · FY 2025 · +8% YoY
- ₹37.4 LakhNet profit · 1% margin
- ₹7.49 CrEBITDA · 13% margin
- ₹4.15 CrPaid-up capital
- 118Employees (provident fund records)
- +8%Revenue CAGR, 3 years
- +26%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Solistaa Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Solistaa
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Solistaa
10 companies that operate in the same segment as Solistaa (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Solistaa
Solistaa is headquartered in Puducherry, India. It is registered at Puducherry, Puducherry, India.
Solistaa has 118 employees.
The primary company behind Solistaa, Solistaa Pharmaceuticals Private Limited, reported revenue of ₹57.79 Cr for FY 2025, up 8% year on year.
Solistaa Pharmaceuticals Private Limited was established in 2017 as a manufacturer of nutraceutical products in India. Facilities are operated in Puducherry and Tamil Nadu, where various dosage forms including gummies, soft chews, tablets, capsules, powders, and oral liquids are produced. High food safety standards such as HACCP and FSSC: 22000 are adhered to, along with GMP compliance. Involvement in pharmaceutical formulation development is noted, with efforts directed towards regulatory filings and expansion into global markets like the USA and Canada.
Solistaa offers Gummies and Tablets.
Solistaa operates through Solistaa Pharmaceuticals Private Limited.
The legal entities of Solistaa currently have 3 directors, including Paramasivan Sivarajakumar, Kandoth Kunnumpreth Vinupal, Sundararajalu.